Clinical Factors Associated with Plasma F₂-Isoprostane Levels in HIV-Infected Adults

REFERENCES

• Walensky RP, Paltiel AD, Losina E, et al. The survival ben-efits of AIDS treatment in the United States. J Infect Dis. 2006;194(1)11–19.
   Web of Science ®Google Scholar
• Morse CG, Kovacs JA. Metabolic and skeletal compli-cations of HIV infection: the price of success. JAMA. 2006;296(7):844–854.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184)1112–1115.
   Web of Science ®Google Scholar
• Dalakas MC, Semino-Mora C, Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab Invest. 2001;81(11): 1537–1544.
   PubMed Web of Science ®Google Scholar
• Day L, Shikuma C, Gerschenson M. Mitochondrial injury in the pathogenesis of antiretroviral-induced hepatic steatosis and lactic acidemia. Mitochondrion. 2004;4 (2-3):95–109.
   PubMed Web of Science ®Google Scholar
• Olinski R, Gackowski D, Foksinski M, Rozalski R, Roszkowski K, Jaruga P. Oxidative DNA damage: assessment of the role in carcinogenesis, atherosclerosis, and acquired immu-nodeficiency syndrome. Free Radic Biol Med. 2002;33(2): 192–200.
   PubMed Web of Science ®Google Scholar
• Früs-Moller N, Reiss P, Sabin CA, et al. Class of antiret-roviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17)1723–1735.
   Web of Science ®Google Scholar
• Day BJ, Lewis W. Oxidative stress in NRTI-induced toxicity: evidence from clinical experience and experi-ments in vitro and in vivo. Cardiovasc ToxicoL 2004;4(3): 207–216.
   PubMedGoogle Scholar
• Montine KS, Quinn JF, Zhang J, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids. 2004;128(1-2):117–124.
   PubMed Web of Science ®Google Scholar
• Shishehbor MH, Zhang R, Medina H, et al. Systemic elevations of free radical oxidation products of arachi-donic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med. 2006;41(11):1678–1683.
   PubMed Web of Science ®Google Scholar
• Gil L, Perez D, Tapanes R, Perez J, Grune T. Does mito-chondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxi-dant supplementation as a beneficial option? Redox Rep. 2005;10(3):113–119.
   Google Scholar
• Dobmeyer TS, Findhammer S, Dobmeyer JM, et al. Ex vivo induction of apoptosis in lymphocytes is mediated by oxidative stress: role for lymphocyte loss in HIV infection. Free Radic Biol Med. 1997;22(5):775–785.
   PubMed Web of Science ®Google Scholar
• Valcour V, Shiramizu B. HIV-associated dementia, mito-chondrial dysfunction, and oxidative stress. Mitochon-drion. 2004;4(2-3):119–129.
   PubMed Web of Science ®Google Scholar
• Stehbens WE. Oxidative stress in viral hepatitis and AIDS. Exp Mol PathoL 2004;77(2)121–132.
   Web of Science ®Google Scholar
• Halliwell B. Lipid peroxidation, antioxidants and cardiovas-cular disease: how should we move forward? Cardiovasc Res. 2000;47(3):410–418.
   PubMed Web of Science ®Google Scholar
• Jaruga P, Jaruga B, Gackowski D, et al. Supplementation with antioxidant vitamins prevents oxidative modification of DNA in lymphocytes of HIV-infected patients. Free Radic Biol Med. 2002;32(5):414–420.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Roberts U. The isoprostanes: unique bio-active products of lipid peroxidation. Prog Lipid Res. 1997;36(1):1–21.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Frei B, Longmire AW, et al. Increase in circu-lating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 1995;332(18)1198–1203.
   Web of Science ®Google Scholar
• Stein CM, Tanner SB, Awad JA, Roberts LJ II, Morrow JD. Evidence of free radical-mediated injury (isopros-tane overproduction) in scleroderma. Arthritis Rheum. 1996;39(7)1 146–1150.
   PubMed Web of Science ®Google Scholar
• Montine TJ, Markesbery WR, Morrow JD, Roberts LJ II. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann NeuroL 1998;44(3):410–413.
   PubMed Web of Science ®Google Scholar
• Konishi M, Lwasa M, Araki J, et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol HepatoL 2006;21(12):1821–1825.
   PubMed Web of Science ®Google Scholar
• Lkizler TA, Morrow JD, Roberts LJ, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002;58(3):190–197.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Morrow JD. Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia. J Acquir Immune Defic Syndr 2003;34(1):45–49.
   PubMed Web of Science ®Google Scholar
• HuIgen T, Morrow J, D'Aquila RT, et al. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis. 2003;37(12):1711–1717.
   PubMed Web of Science ®Google Scholar
• Morrow JD, Roberts LJ II. Mass spectrometric quantifica-tion of F2-isoprostanes as indicators of oxidant stress. Methods Mol Biol. 2002;186:57–66.
   PubMedGoogle Scholar
• Turner ML, Reed-Walker K, King JR, Acosta EP. Simulta-neous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784(2):331–341.
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr. Regression Modeling Strategies: With Appli-cations to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Verlag; 2001.
   Google Scholar
• Keaney JF Jr, Larson MG, Vasan RS, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434–439.
   PubMed Web of Science ®Google Scholar
• Block G, Dietrich M, Norkus EP, et al. Factors associated with oxidative stress in human populations. Am J Epide-mioL 2002;156(3):274–285.
   PubMed Web of Science ®Google Scholar
• Gross M, Steffes M, Jacobs DR Jr, et al. Plasma F2-isoprostanes and coronary artery calcification: the CARDIA Study. Clin Chem. 2005;51(1):125–131.
   PubMed Web of Science ®Google Scholar
• Ide T, Tsutsui H, Ohashi N, et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol. 2002;22(3):438–442.
   PubMed Web of Science ®Google Scholar
• Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS. 2000;14(7):807–812.
   PubMed Web of Science ®Google Scholar
• Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodefi-ciency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab. 2003;88(11):5186–5192.
   PubMed Web of Science ®Google Scholar
• Negredo E, Ribalta J, Paredes R, et al. Reversal of athero-genic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevi-rapine. AIDS. 2002;16(10):1383–1389.
   PubMed Web of Science ®Google Scholar
• Petit JM, Duong M, Masson D, et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest. 2004;34(8):569–575.
   PubMed Web of Science ®Google Scholar
• Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004;20(6):589–594.
   PubMed Web of Science ®Google Scholar
• Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviral-naive patients starting Pl- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005;10(5):585–591.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Kastelein JJ, Murphy RU, et al. Nevirap-ine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS. 2001;15(18):2407–2414.
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R. Efa-virenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007;45(2):263–266.
   PubMed Web of Science ®Google Scholar
• Clotet B, van der Valk M, Negredo E, Reiss P. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 2003;34(Suppl 1):579–84.
   Google Scholar
• van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiret-roviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1(1):e19.
   PubMed Web of Science ®Google Scholar
• Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsy-chiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006;20(8):542–548.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Calza L, Chiodo F. An extremely differ-ent dysmetabolic profile between the two avail-able nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr. 2005;38(2):236–238.
   PubMed Web of Science ®Google Scholar
• El Hadri K, Glorian M, Monsempes C, et al. In vitro sup-pression of the lipogenic pathway by the nonnucleo-side reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem. 2004;279(15)1 5130–15141.
   Web of Science ®Google Scholar
• Hulgan T, Hughes M, Sun X, et al. Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. J Acquir Immune Defic Syndr 2006;42(4):450–454.
   PubMed Web of Science ®Google Scholar